Calidi Biotherapeutics, Inc.
Income Statement
| Line Item | FY2022 |
|---|---|
| Revenue | $45.0K |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $7.3M |
| SG&A Expense | $15.9M |
| Operating Income | $-23.1M |
| Operating Margin | -51,395.6% |
| Interest Expense | $200.0K |
| Pretax Income | $-25.4M |
| Income Tax Expense | $11.0K |
| Net Income | $-25.4M |
| Net Margin | -56,504.4% |
| EPS (Basic) | $0.60 |
| EPS (Diluted) | $0.60 |
| Shares Outstanding (Basic) | 42.5M |
| Shares Outstanding (Diluted) | 42.5M |
| Dividends Per Share | — |